Prior Authorization Denials Hit 42%: The Real Impact for Biologics Access
A 42% denial rate for biologics prior authorizations through CVS Caremark in the first half of 2026 says plenty about what’s happening in the pharmacy benefit manager world right now. This number isn’t from a think tank press release; it’s surfaced in hard employer claims audits assembled by RxInfo.ai and lines up with specialty pharmacy revenue misses in Q1. The benchmark? Just two years ago, large employer plans saw denials under 29%. Today, nearly half of initial requests for biologic therapies are turned away, stalled, or outright rejected on first pass.
These are not just isolated cases involving marginal therapies. Even leaders like Humira biosimilars and GLP-1 receptor agonists see over 30% of approvals hit with denials or demands for additional paperwork. Providers? Their teams are stuck churning through appeals and peer-to-peer reviews, diverting clinical resources and administrative muscle away from actual care. None of that gets mentioned in PBM press statements, of course. For patients, this means stretched treatment timelines and rising abandonment rates, especially acute in autoimmune and rare disease categories where time to therapy is directly tied to outcomes.
On the other side, payers and CVS defend the trend as rational cost containment, a counterweight to relentless biologic inflation. But specialty pharmacies and patients carry the operational, and clinical, costs. As rebate pools shrink and gross-to-net margins come under pressure, it’s clear PBMs are turning prior authorization into their lead tool for defending margin. The environment has changed, and not in the patient’s favor.
How CVS Health’s PBM Model Drives Denials and Margin
Look under the surface at CVS Health’s PBM numbers, and the strategy comes into focus. In 2025, CVS Caremark pulled $8.9 billion in operating profit, with specialty drugs and services making up more than 60% of segment earnings. As biosimilar competition pushed down list prices, rebate pools dried up fast. The PBM business used to thrive on volume guarantee deals with AbbVie, Amgen, and biosimilar entrants, but those arrangements can’t keep up with aggressive employer demands for lower net costs.
So, CVS doubled down on utilization management. Prior authorization, ever the broad tool, was honed, algorithms flag prescriber and patient patterns, step therapies stack up, and denials shape the flow. Not just bureaucratic hurdles: denials have turned into a financial lever. They let CVS show employer clients they’re working to curb drug spend, but they also pump up profit. The math isn’t subtle. For every $1 million in specialty claims denied, nearly $90,000 lands in PBM segment margin, since overhead remains mostly fixed. With $60 billion in annual specialty claims under its belt, even a modest 5% increase in denials is good for $270 million in margin. That gets attention in the C-suite.
This approach also changes the negotiating landscape with drugmakers. When a novel biologic or biosimilar launches, CVS can credibly threaten exclusion or restriction, pressuring for bigger discounts or service fees. Manufacturers, watching list prices drop but unsure if volume will follow, find themselves forced to offer better terms or risk their drug stalling out at launch. Not a comfortable position.
Provider and Pharmacy Fallout: Friction at the Front Lines
Specialty pharmacies have felt the pinch first, and the hardest. Over the past year, four regional specialty pharmacies reported year-over-year declines in new biologic starts, blaming administrative denials and lengthening prior authorization cycles. According to RxPBM.ai claims data, the average time from prescription to first fill for autoimmune biologics in CVS networks hit 17 days in 2026, compared to just 11 days before 2024. Not just a paperwork lag. That’s delayed cash flow, slower patient care, and a real revenue gap for pharmacies.
Provider offices haven’t been spared. Many report stricter step therapy requirements, rerouting patients to preferred biosimilars or lower-cost options, often ignoring clinical subtleties. Some clinics now see first-pass approval rates under 50% for flagship biologics, forcing staff to double up on appeals and paperwork chases that drag on for months. Every denied claim is wasted FTE effort and a ticking clock toward prescription abandonment.
Employer coalitions have started pushing back, if quietly. Several Fortune 100 benefits leaders are now demanding real-time prior authorization dashboards and transparency around denial rationales and appeals processing speed from CVS. For employer plans using specialty carve-outs, these shifting rules create unpredictable out-of-pocket costs for members and chaotic swings in annual spend.
What Regulatory Scrutiny Means for CVS and the Channel
Regulators are starting to step in. Four states have moved forward with bills mandating faster PA timelines and clearer appeal procedures. Meanwhile, the delayed CMS 2025 rule changes, likely to arrive in 2027, will require PBMs like CVS to publish overall denial and appeal data for the first time. That kind of daylight could disrupt the status quo, especially if denial rates keep hovering above 40%. The old “black box” approach to utilization management isn’t built for this degree of scrutiny.
For CVS, this brings both risk and a certain amount of power. Managing about a third of all US specialty benefit claims gives it the clout to set access standards. But size is a double-edged sword: regulatory attention grows, and large self-insured employers are already evaluating specialty carve-outs or pass-through pricing. That would threaten Caremark’s core margin model. CVS has talked a big game about patient support and “value-based” contracts, but the numbers don’t impress, support spending up just 3%, while denial rates from prior auth jumped 12% year over year. Sounds like window dressing.
Where does it go from here? For biosimilar manufacturers hoping to break through the denial logjam, offering low prices won’t be enough. They’ll need to streamline administrative demands and provide convincing real-world evidence to shortcut lengthy PA cycles. For now, CVS holds the upper hand, and the downside for providers and patients is measured less in dollars than in extra weeks waiting for therapy.
More detail on pricing and contract trends? See RxInfo.ai. For PBM segment numbers, RxPBM.ai drills down further.
